medlogicai.org

Clinical intelligence. Better decisions.

Decision-Making Algorithm in Otorhinolaryngology & Head and Neck Surgery

Glottic & Subglottic Carcinoma

Hoarseness to transglottic cancer — staging, transoral laser, radiotherapy, organ-preservation, and salvage laryngectomy

Step 1

Step 1 of 14

Clinical Presentation

Voice · swallowing · pain · airway · neck · constitutional symptoms

Glottic and subglottic carcinoma announces itself early through the voice and late through the airway. Voice symptoms — persistent hoarseness beyond 2–3 weeks, voice fatigue, and a change in voice quality — are the earliest and commonest, because even a small glottic tumour disturbs cord vibration. Swallowing symptoms (dysphagia, odynophagia) and pain (referred otalgia via the vagus, throat pain) suggest more advanced or supraglottic/hypopharyngeal extension.

Airway symptoms — dyspnoea, stridor, frank obstruction — signal a bulky or subglottic tumour and demand urgent assessment. A neck mass reflects nodal metastasis (uncommon in early glottic disease, more frequent with subglottic or advanced tumours). Constitutional features (weight loss) and the risk exposures of tobacco and alcohol complete the picture. The key clinical reflex is simple: hoarseness that persists must be scoped, never simply treated as reflux or laryngitis.

  • Voice — persistent hoarseness >2–3 weeks, voice fatigue, quality change (earliest, commonest)
  • Swallowing — dysphagia, odynophagia; Pain — referred otalgia, throat pain
  • Airway — dyspnoea, stridor, obstruction (bulky/subglottic tumour)
  • Neck — mass (nodal metastasis); General — weight loss
  • Exposures — tobacco, alcohol

Key statistics

  • Earliest sign of glottic cancer

    hoarseness

    Hoarseness is the earliest and most common presenting symptom of glottic cancer; persisting beyond 2–3 weeks it mandates laryngoscopy. US national data document its epidemiology and the much-debated decline in survival over recent decades.

    PMID 16946667

★ High-yield pearls (chapter-wide)

  • Hoarseness persisting beyond 2–3 weeks is laryngeal cancer until the larynx is visualised — every such patient needs laryngoscopy, not another course of reflux therapy.
  • Vocal-cord mobility is the cornerstone of glottic T staging — impaired mobility is T2, fixation is T3; assess it carefully before anything else changes management.
  • Early glottic cancer rarely spreads to cervical nodes because the true cords have almost no lymphatics — the N0 neck usually needs no treatment.
  • Subglottic cancer is rare, presents late, and carries a high paratracheal (level VI) nodal risk — include the paratracheal and lower-neck nodes in the treatment volume.
  • Larynx preservation is not the same as functional-larynx preservation — a severely dysfunctional, aspirating larynx after chemoradiotherapy can be worse than a well-rehabilitated total laryngectomy.
  • Stridor, cord fixation, a large transglottic tumour, or subglottic obstruction is an airway emergency — secure the airway (awake fibreoptic or tracheostomy) before completing the work-up.
  • T1–T2 glottic cancer is cured in roughly 90% by either transoral laser microsurgery or radiotherapy — the choice turns on voice outcome, anterior-commissure involvement, and patient factors.
  • Salvage total laryngectomy is the most reliable treatment for disease persisting or recurring after chemoradiotherapy — and flap reinforcement reduces the pharyngocutaneous fistula rate.
  • Positive margins or extracapsular nodal extension after surgery are the two features that mandate concurrent cisplatin chemoradiotherapy, not radiotherapy alone.
  • Anterior-commissure involvement and impaired cord mobility predict radiotherapy and laser failure — flag them at staging and counsel accordingly.

Evidence base

3 sources
  1. HIGH

    Steuer CE, El-Deiry M, Parks JR · CA Cancer J Clin · 2017ReviewPMID 27898173

    Comprehensive review anchoring epidemiology, staging, and stage-directed management of laryngeal cancer.

  2. MOD

    Hoffman HT, Porter K, Karnell LH · Laryngoscope · 2006National database studyPMID 16946667

    Landmark US database study of laryngeal-cancer demographics, treatment patterns, and the much-debated survival decline.

  3. MOD

    Obid R, Redlich M, Tomeh C · Oral Maxillofac Surg Clin North Am · 2019ReviewPMID 30449522

    Practical treatment review across early and advanced glottic and subglottic disease.

Decision tree

The triage screen is the first gate. Classification routes the stable patient to one of the aetiology-keyed pathways below. Cross-cut cards capture the chapter's must-not-miss rules.

Step 1 — TriageRed-flag screenNo red flagPathway classification?TLM (A)CIS / early glottic — endoscopic CO₂-laser cordectomy;repeatable, RT in reserveRadiotherapy (B)Early glottic — hypofractionated IMRT; ~90% local control,good voicePartial laryngectomy (C)Selected T2/T3 — vertical or supracricoid; needs pulmonaryreserveChemoradiotherapy (D)Advanced, preservation candidate — cisplatin + IMRT; salvagein reserveTotal laryngectomy (E)Advanced non-candidate — removes larynx + stoma; TEP voicerehabSubglottic (F)Rare, late, paratracheal-node prone — IMRT + chemo coveringlevel VINeck (G)N0 often untreated in early glottic; N+ dissection/CRT; levelVI if subglotticSalvage (H)Recurrence after RT — salvage laryngectomy; flap reinforcementcuts fistulaRecurrent/metastatic (I)PD-L1-guided pembrolizumab; nivolumab after platinum;palliative RTRehab/survivorship (J)TEP / electrolarynx; second-primary surveillance; lateRT-effect carePathways:A TLMB RadiotherapyC Partial laryngectomyD ChemoradiotherapyE Total laryngectomyF SubglotticG NeckH SalvageI Recurrent/metastaticJ Rehab/survivorship
Step 1

Disclaimer

For educational purposes only. Not for clinical use. This platform is an instructional resource intended to support learning about clinical decision-making and the interpretation of investigations. Clinicians remain completely responsible for the interpretation of findings, the formulation of a differential diagnosis, and any clinical decision. Nothing in this application replaces individualized assessment, hands-on training, expert consultation, or established practice guidelines.

Not for profit effort by

Dr. Prahlada N.B

  • MBBS (JJMMC), MS (PGIMER, Chandigarh)
  • MBA in Hospital & Healthcare Management (BITS, Pilani)
  • Postgraduate Certificate in Technology Leadership and Innovation (MIT, USA)
  • Executive Programme in Strategic Management (IIM, Lucknow)
  • Senior Management Programme in Healthcare Management (IIM, Kozhikode)
  • Advanced Certificate in AI for Digital Health and Imaging Program (IISc, Bengaluru)

Supporting organisations

  • Karnataka ENT Hospital and Research Centre (R)
  • Champions Educational and Medical Society (R)
  • Amogh Foundation